Funding in the AI drug discovery sector has grown from $1bn globally in 2015 to over $10bn in 2020. The cost to bring new drugs to market has been doubling every decade to more than $2bn lately. Coupled with drug pricing pressures, patent cliffs and decreasing R&D productivity, pharma is experiencing a perfect storm.
As one of the most active European digital health and biotech investors, we believe that AI and modern computing hold key to solving some of pharmaceutical industry's biggest problems. Read sector deep-dive here.
Who is driving European AI drug discovery market? We've segmented European AI drug discovery startups according to their place in the drug discovery and development stage they primarily operate in plus their commercial models.